Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats
Yıl: 2019 Cilt: 3 Sayı: 1 Sayfa Aralığı: 37 - 42 Metin Dili: İngilizce DOI: 10.14744/ejmo.2018.0008 İndeks Tarihi: 22-04-2020
Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats
Öz: Objectives: Bleeding control is crucial in preventing negative consequences by reducing blood loss in surgical operations. The aim of this study is to evaluate the hemostatic effect of a new herbal hemostatic agent called Algan Hemostatic Agent (AHA) in an uncontrolled bleeding model made by liver laceration.Methods: In these study 5–7 weeks-old 64 rats were used. Rats were randomly divided into 8 groups each consistingof eight rats (4 groups heparinize and 4 groups non-heparinize). The experimental liver laceration was performed, andphysiological serum impregnated gauze was applied to the control group for hemorrhage control, AHA liquid formimpregnated gauze, AHA gel, and AHA powder form were applied to experimental groups, respectively.Results: The shortest bleeding time was found in the AHA powder group. The AHA powder form stopped the bleedingin the heparinize group for a mean of 4 s, the non-heparinized group for 2 s. This was followed by the gel group and theliquid group. The bleeding time was significantly shorter in the all AHA group compared to the control group.Conclusion: This study showed that AHA is a highly effective hemostatic agent in controlling bleeding compared tothe control group.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Romano F, Franciosi C, Caprotti R, Uggeri F. Hepatic surgery using the ligasure vessel sealing system. World J Surg 2005;29:110–2.
- 2. Kopelman D, Klein Y, Zaretsky A, Ben-Izhak O, Michaelson M, Hashmonai M, et al. Cryohemostasis of uncontrolled hemorrhage from liver injury. Cryobiology 2000;40:210–7.
- 3. Carmona RH, Lim RC Jr. Clark GC. Morbidity and mortality in hepatic trauma. A 5 year study. Am J Surg 1982;144:88–94.
- 4. Laurent C, Blanc JF, Nobili S, Sa Cunha A, le Bail B, Bioulac-Sage P, et al. Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005;201:656–62.
- 5. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397–406.
- 6. Ruitenbeek K, Ayez N, Verhoef C, de Wilt JH, Bottema J, Rijken AM, et al. Safety and efficacy of a novel, dry powder fibrin sealant for hemostasis in hepatic resection. Dig Surg 2014;31:422–7.
- 7. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology 1998;37:171–86.
- 8. Ersoy G, Kaynak MF, Yilmaz O, Rodoplu U, Maltepe F, Gokmen N, et al. Hemostatic effects of microporous polysaccharide hemosphere in a rat model with severe femoral artery bleeding. Adv Ther 2007;24:485–92.
- 9. Saiura A, Yamamoto J, Koga R, Sakamoto Y, Kokudo N, Seki M, et al. Usefulness of ligaSure for liver resection: Analysis by randomized clinical trial. Am J Surg 2006;192:41–5.
- 10. Davidson BR, Burnett S, Javed MS, Seifalian A, Moore D, Doctor N, et al. Experimental study of a novel fibrin sealant for achieving haemostasis following partial hepatectomy. Br J Surg 2000;87:790–5.
- 11. CoStasis Multi-center Collaborative Writing Committee. A novel collagen-based composite offers effective hemostasis for multiple surgical indications: Results of a randomized controlled trial. Surgery 2001;129:445–50.
- 12. Nakajima Y, Shimamura T, Kamiyama T, Matsushita M, Sato N, Todo S, et al. Control of intraoperative bleeding during liver resection: Analysis of a questionnaire sent to 231 Japanese hospitals. Surg Today 2002;32:48–52.
- 13. Akarsu C, Kalaycı MU, Yavuz E, Ozkara S, Gökçek B, Ozdenkaya Y, et al. Comparison of the hemostatic efficiency of ankaferd blood stopper and fibrin glue on a liver laceration model in rats. Ulus Travma Acil Cerrahi Derg 2011;17:308–12.
- 14. Jackson MR. New and potential uses of fibrin sealants as an adjunct to surgical hemostasis. Am J Surg 2001;182:36S–39S.
- 15. Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, et al. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 2004;139:1148–54.
- 16. Fischer L, Seiler CM, Broelsch CE, de Hemptinne B, Klempnauer J, Mischinger HJ, et al. Hemostatic efficacy of tachoSil in liver resection compared with argon beam coagulator treatment: An open, randomized, prospective, multicenter, parallel-group trial. Surgery 2011;149:48–55.
- 17. Koea JB, Batiller J, Patel B, Shen J, Hammond J, Hart J, et al. A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB (Oxford) 2013;15:61–70.
- 18. Frilling A, Stavrou GA, Mischinger HJ, de Hemptinne B, Rokkjaer M, Klempnauer J, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: A randomised prospective trial. Langenbecks Arch Surg 2005;390:114–20.
- 19. Berrevoet F, de Hemptinne B. Clinical application of topical sealants in liver surgery: Does it work? Acta Chir Belg 2007;107:504–7.
- 20. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. Evaluation of hemostatic effects of ankaferd as an alternative medicine. Altern Med Rev 2010;15:329–36.
- 21. Aysan E, Bektas H, Ersoz F, Sari S, Kaygusuz A, Huq GE, et al. Ability of the ankaferd blood stopper® to prevent parenchymal bleeding in an experimental hepatic trauma model. Int J Clin Exp Med 2010;3:186–91.
- 22. Dorterler ME, Ayangil HR, Turan C, Deniz K. Comparison of the hemostatic effects of oxidized cellulose and calcium alginate in an experimental animal model of hepatic parenchymal bleeding. Int J Crit Illn Inj Sci 2016;6:167–71.
- 23. Satar NY, Akkoc A, Oktay A, Topal A, Inan K. Evaluation of the hemostatic and histopathological effects of ankaferd blood stopper in experimental liver injury in rats. Blood Coagul Fibrinolysis 2013;24:518–24.
- 24. MacDonald MH, Wang AY, Clymer JW, Hutchinson RW, Kocharian R. An in vivo comparison of the efficacy of hemostatic powders, using two porcine bleeding models. Med Devices (Auckl) 2017;10:273–9.
- 25. Kim SH, Yoon HS, In CH, Kim KS. Efficacy evaluation of surgiGuard® in partially hepatectomized pigs. Korean J Hepatobiliary Pancreat Surg 2016;20:102–9.
| APA | Midi A, KUMANDAS A, EKİCİ H, BAYRAKTAR F, KARAPİRLİ K, Karahan S, Türk M, ÖZYÜREK H (2019). Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. , 37 - 42. 10.14744/ejmo.2018.0008 |
| Chicago | Midi Ahmet,KUMANDAS ALI,EKİCİ Hüsamettin,BAYRAKTAR Feyzanur,KARAPİRLİ Kübra,Karahan Siyami,Türk Mustafa,ÖZYÜREK H. Emel Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. (2019): 37 - 42. 10.14744/ejmo.2018.0008 |
| MLA | Midi Ahmet,KUMANDAS ALI,EKİCİ Hüsamettin,BAYRAKTAR Feyzanur,KARAPİRLİ Kübra,Karahan Siyami,Türk Mustafa,ÖZYÜREK H. Emel Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. , 2019, ss.37 - 42. 10.14744/ejmo.2018.0008 |
| AMA | Midi A,KUMANDAS A,EKİCİ H,BAYRAKTAR F,KARAPİRLİ K,Karahan S,Türk M,ÖZYÜREK H Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. . 2019; 37 - 42. 10.14744/ejmo.2018.0008 |
| Vancouver | Midi A,KUMANDAS A,EKİCİ H,BAYRAKTAR F,KARAPİRLİ K,Karahan S,Türk M,ÖZYÜREK H Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. . 2019; 37 - 42. 10.14744/ejmo.2018.0008 |
| IEEE | Midi A,KUMANDAS A,EKİCİ H,BAYRAKTAR F,KARAPİRLİ K,Karahan S,Türk M,ÖZYÜREK H "Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats." , ss.37 - 42, 2019. 10.14744/ejmo.2018.0008 |
| ISNAD | Midi, Ahmet vd. "Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats". (2019), 37-42. https://doi.org/10.14744/ejmo.2018.0008 |
| APA | Midi A, KUMANDAS A, EKİCİ H, BAYRAKTAR F, KARAPİRLİ K, Karahan S, Türk M, ÖZYÜREK H (2019). Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. Eurasian Journal of Medicine and Oncology, 3(1), 37 - 42. 10.14744/ejmo.2018.0008 |
| Chicago | Midi Ahmet,KUMANDAS ALI,EKİCİ Hüsamettin,BAYRAKTAR Feyzanur,KARAPİRLİ Kübra,Karahan Siyami,Türk Mustafa,ÖZYÜREK H. Emel Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. Eurasian Journal of Medicine and Oncology 3, no.1 (2019): 37 - 42. 10.14744/ejmo.2018.0008 |
| MLA | Midi Ahmet,KUMANDAS ALI,EKİCİ Hüsamettin,BAYRAKTAR Feyzanur,KARAPİRLİ Kübra,Karahan Siyami,Türk Mustafa,ÖZYÜREK H. Emel Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. Eurasian Journal of Medicine and Oncology, vol.3, no.1, 2019, ss.37 - 42. 10.14744/ejmo.2018.0008 |
| AMA | Midi A,KUMANDAS A,EKİCİ H,BAYRAKTAR F,KARAPİRLİ K,Karahan S,Türk M,ÖZYÜREK H Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 37 - 42. 10.14744/ejmo.2018.0008 |
| Vancouver | Midi A,KUMANDAS A,EKİCİ H,BAYRAKTAR F,KARAPİRLİ K,Karahan S,Türk M,ÖZYÜREK H Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 37 - 42. 10.14744/ejmo.2018.0008 |
| IEEE | Midi A,KUMANDAS A,EKİCİ H,BAYRAKTAR F,KARAPİRLİ K,Karahan S,Türk M,ÖZYÜREK H "Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats." Eurasian Journal of Medicine and Oncology, 3, ss.37 - 42, 2019. 10.14744/ejmo.2018.0008 |
| ISNAD | Midi, Ahmet vd. "Investigation of the Efficacy of Algan Hemostatic Agent in Liver Laceration Model in Rats". Eurasian Journal of Medicine and Oncology 3/1 (2019), 37-42. https://doi.org/10.14744/ejmo.2018.0008 |
